MktsMarkets

Beam Therapeutics Inc.
NASDAQ: BEAMKey statistics
BEAM News
Stories mentioning BEAM from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 31,738 | 114,109 | 9,698 | 8,466 | 7,470 | 30,067 | 14,269 | 11,772 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 104,524 | 99,275 | 109,769 | 101,758 | 98,816 | 101,444 | 94,258 | 87,041 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 138,953 | 131,554 | 136,509 | 128,617 | 126,756 | 130,104 | 120,773 | 116,667 |
| Operating Income (Loss) | (107,215) | (17,445) | (126,811) | (120,151) | (119,286) | (100,037) | (106,504) | (104,895) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | (112,728) | (102,291) | (96,668) | (91,012) | ||||
| Tax Provision | 0.00 | 0.00 | 39.00 | |||||
| Net Income (Loss) | (94,318) | 243,357 | (112,728) | (102,291) | (108,330) | (90,354) | (96,668) | (91,051) |
| Earnings Per Share (Basic) | (0.91) | 2.46 | (1.10) | (1.00) | (1.23) | (1.10) | (1.17) | (1.11) |
| Earnings Per Share (Diluted) | (0.91) | 2.46 | (1.10) | (1.00) | (1.23) | (1.10) | (1.17) | (1.11) |
| Weighted Average Shares Outstanding (Basic) | 103,262 | 98,906 | 102,571 | 101,995 | 87,975 | 82,313 | 82,410 | 82,312 |
| Weighted Average Shares Outstanding (Diluted) | 103,262 | 98,906 | 102,571 | 101,995 | 87,975 | 82,313 | 82,410 | 82,312 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About BEAM
Beam Therapeutics Inc. (NASDAQ: BEAM) is a stock listed on the Nasdaq Stock Market under the ticker symbol BEAM. It last traded at $27.12 (Nov 9, 2026, 2:34 PM ET), up 2.7% on the day. That gives Beam Therapeutics a market capitalisation of $2.7B.
Over the past 52 weeks BEAM has traded between $20.23 and $38.26.
Revenue for the quarter ended Mar 31, 2026 was $31.7M; a net loss of $94.3M. Revenue was up 325% from $7.5M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $31.7M | -$94.3M | -297.2% |
| Dec 31, 2025 | $114.1M | $243.4M | 213.3% |
| Sep 30, 2025 | $9.7M | -$112.7M | -1162.4% |
| Jun 30, 2025 | $8.5M | -$102.3M | -1208.3% |
From Beam Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…